Company Overview
Snapshot
Founded in January 2005 by Alon Blankstein, Allan Aginsky, and Dr. Doron Friedman, CapsuLINT operates with 1–10 employees. The company holds a patent for its core technology.
Business overview
CapsuLINT is a pharmaceutical company focused on developing an oral drug delivery system. Its patented technology is designed to enhance the dissolution, permeability, and oral absorption of low-solubility and/or low-permeability drugs through a nano-size amorphous dispersion. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical industry with its B2B business model and products like Docetaxel.
Log in to access full profile ›Company Intelligence Q&A
- What is CapsuLINT's primary focus?
- CapsuLINT is primarily focused on developing a patented oral drug delivery system designed to improve the absorption of low-solubility and low-permeability drugs.
- When was CapsuLINT founded?
- CapsuLINT was founded in January 2005.
- Who are the founders of CapsuLINT?
- CapsuLINT was founded by Alon Blankstein, Allan Aginsky, and Dr. Doron Friedman.
- Does CapsuLINT hold any patents?
- Yes, CapsuLINT holds a patent for its oral drug delivery system.
- What is CapsuLINT's business model?
- CapsuLINT operates on a B2B business model, targeting the pharmaceutical industry.